ROMVIMZA® (Vimseltinib)

The FDA on February 14, 2025, approved ROMVIMZA®, a kinase inhibitor, for adult patients with symptomatic Tenosynovial Giant Cell Tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ROMVIMZA® is a product of Deciphera Pharmaceuticals, LLC.